Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
MaxCyte Inc (GB:MXCT)
LSE:MXCT
MaxCyte (MXCT) Share Price & Analysis
7 Followers
MXCT Stock Chart & Stats
Day’s Range0p - 0p
52-Week Range170.00p - 430.00p
Previous Close323p
Volume16.66K
Average Volume (3M)28.02K
Market Cap
£317.48M
Enterprise Value197.48M
Total Cash (Recent Filing)$168.29M
Total Debt (Recent Filing)$18.74M
Price to Earnings (P/E)-11.9
Beta1.62
Next Earnings
May 07, 2024EPS Estimate
-£0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.29
Shares Outstanding100,434,032
10 Day Avg. Volume325,587
30 Day Avg. Volume28,015
Standard Deviation0.16
R-Squared0.00533
Alpha0.05
Financial Highlights & Ratios
Price to Book (P/B)2.61
Price to Sales (P/S)38.34
Price to Cash Flow (P/CF)N/A
P/FCF Ratio-55.50
Enterprise Value/Market CapN/A
Enterprise Value/Revenue4.78
Enterprise Value/Gross Profit5.40
Enterprise Value/Ebitda-8.79
Forecast
1Y Price Target
601.82pPrice Target Upside104.01% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
MaxCyte News
PremiumCompany Announcements
MaxCyte Expands Stock Capital, Supports Cell Therapy
Bulls Say, Bears Say
Bulls Say
Financial DisciplineMXCT's total cash and cash equivalents are higher than expected, indicating increased financial discipline and successful milestone achievements.
Market ConfidenceMXCT shares rose on UK approval, signaling market confidence in the company's technology and potential for growth.
Product ApprovalThe approval of exa-cel in both the US and UK has positively impacted MXCT's revenue.
Bears Say
Earnings ReportQ3 revenue of $8.0M (-25% Y/Y) missed analyst's expectations of $9.0M and was significantly below the Street's $11.3M estimate.
Financial GuidanceMXCT management has lowered FY24 revenue guidance, reflecting potential challenges ahead.
Stock PerformanceShares of MXCT, which are down a modest 5%.
---
Options Prices
Currently, No data available
---
Ownership Overview
10.56% Insiders
20.15% Mutual Funds
10.07% Other Institutional Investors
59.22% Public Companies and
Individual Investors
MXCT FAQ
What was MaxCyte Inc’s price range in the past 12 months?
MaxCyte Inc lowest share price was 170.00p and its highest was 430.00p in the past 12 months.
What is MaxCyte Inc’s market cap?
Currently, no data Available
When is MaxCyte Inc’s upcoming earnings report date?
MaxCyte Inc’s upcoming earnings report date is May 07, 2024 which is in 5 days.
How were MaxCyte Inc’s earnings last quarter?
MaxCyte Inc released its earnings results on Mar 12, 2024. The company reported -0.04p earnings per share for the quarter, beating the consensus estimate of -0.055p by 0.015p.
Is MaxCyte Inc overvalued?
According to Wall Street analysts MaxCyte Inc’s price is currently Undervalued.
Does MaxCyte Inc pay dividends?
MaxCyte Inc does not currently pay dividends.
What is MaxCyte Inc’s EPS estimate?
MaxCyte Inc’s EPS estimate is -£0.1.
How many shares outstanding does MaxCyte Inc have?
MaxCyte Inc has 104,128,650 shares outstanding.
What happened to MaxCyte Inc’s price movement after its last earnings report?
MaxCyte Inc reported an EPS of -0.04p in its last earnings report, beating expectations of -0.055p. Following the earnings report the stock price went up 3.968%.
Which hedge fund is a major shareholder of MaxCyte Inc?
Currently, no hedge funds are holding shares in GB:MXCT
---
MaxCyte Stock Smart Score
Not Ranked
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
601.82p (104.01% Upside)
601.82p (104.01% Upside)
Blogger Sentiment
Bullish
GB:MXCT Sentiment 100%
Sector Average 70%
Sector Average 70%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-24.69%
12-Months-Change
Fundamentals
Return on Equity
-15.51%
Trailing 12-Months
Asset Growth
-11.69%
Trailing 12-Months
Company Description
MaxCyte Inc
MaxCyte Inc operates in the United States healthcare sector. It develops proprietary electroporation technology, which used blood cells instead of traditional chemical methods to transport medical gene therapies to targeted sites, increasing their safety and efficacy. The company technology finds its use in biotechnology and pharmaceutical firms engaged in cell therapy, including gene editing and immuno-oncology and in drug discovery, development, and biomanufacturing. Its products include MaxCyte STX, VLX, and GT. The company application includes Cell/Gene Therapy, Protein Production, Cell-based Assays, Gene Editing, Cell Line Development, and Viral Vectors/Vaccines. It acquires its income principally from the sale or lease of instruments and processing assemblies.
---
MXCT Stock 12 Months Forecast
Average Price Target
601.82p
▲(104.01% Upside)
Technical Analysis
Best Analysts Covering MXCT
1 Year
1 Year Success Rate
3/18 ratings generated profit
1 Year Average Return
-14.96%
reiterated a buy rating 2 months ago
Copying Mark Massaro's trades and holding each position for 1 Year would result in 16.67% of your transactions generating a profit, with an average return of -14.96% per trade.
---